CHU Martinique, UF1441 Registre des cancers de la Martinique, Pôle de Cancérologie Hématologie Urologie Pathologie, CS 90632, 97200, Fort-de-France, Martinique, France.
CHU Toulouse Paule de Viguier, Groupe de recherche en fertilité humaine EA 3694, Toulouse, France.
BMC Cancer. 2018 Nov 16;18(1):1130. doi: 10.1186/s12885-018-5047-5.
The French West-Indies rank first for both prostate cancer incidence and mortality rates. Analyzing diagnostic and therapeutic procedures among patients with prostate cancer, using data from a population-based cancer registry, is essential for cancer surveillance and research strategies.
This retrospective observational cohort study was based on data from the Martinique Cancer Registry. Records of 452 patients diagnosed with prostate cancer in 2013 were retrieved from the registry. Data extracted were: socio-demographic and clinical characteristics, circumstances of diagnosis, PSA level at diagnosis, Gleason score and risk of disease progression. Stage at diagnosis and patterns of care among prostate cancer patients were analyzed.
Mean age at diagnosis was 67 ± 8 years; 103 (28.5%) were symptomatic at diagnosis. Digital rectal exam was performed in 406 (93.8%). Clinical stage was available in 385 (85.2%); tumours were localized in 322/385 (83.6%). Overall, 17.9% were at low risk, 36.4% at intermediate and 31.9% at high risk; 13.8% were regional/metastatic cancers. Median PSA level at diagnosis was 8.16 ng/mL (range 1.4-5000 ng/mL). A total of 373 patients (82.5%) received at least one treatment, while 79 (17.5%) had active surveillance or watchful waiting. Among patients treated with more than one therapeutic strategy, the most frequent combination was external radiotherapy with androgen deprivation (n = 102, 22.6%).
This study provides detailed data regarding the quality of diagnosis and management of patients with prostate cancer in Martinique. Providing data on prostate cancer is essential for the development of high-priority public health measures for the Caribbean.
法属西印度群岛的前列腺癌发病率和死亡率均居世界首位。通过分析基于人群的癌症登记处的前列腺癌患者的诊断和治疗程序，对于癌症监测和研究策略至关重要。
本回顾性观察性队列研究基于马提尼克癌症登记处的数据。从登记处中检索到 2013 年诊断为前列腺癌的 452 例患者的记录。提取的数据包括：社会人口统计学和临床特征、诊断情况、诊断时 PSA 水平、Gleason 评分和疾病进展风险。分析了前列腺癌患者的诊断阶段和治疗模式。
诊断时的平均年龄为 67±8 岁；103 例（28.5%）在诊断时出现症状。406 例（93.8%）进行了直肠指检。385 例（85.2%）有临床分期资料；322/385 例（83.6%）肿瘤局限于局部。总体而言，17.9%为低危，36.4%为中危，31.9%为高危；13.8%为局部/转移性癌症。诊断时的中位 PSA 水平为 8.16ng/ml（范围 1.4-5000ng/ml）。共有 373 例（82.5%）患者接受了至少一种治疗，而 79 例（17.5%）患者接受了主动监测或观察等待。在接受多种治疗策略的患者中，最常见的联合治疗是外部放疗联合雄激素剥夺（n=102，22.6%）。
本研究提供了马提尼克岛前列腺癌患者诊断和治疗质量的详细数据。提供前列腺癌的数据对于制定加勒比地区的重点优先公共卫生措施至关重要。
